A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE2

מצבים רפואיים

Non-segmental Vitiligo

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • Cahaba Derm and skin hlth ctr 27, Birmingham, Alabama, United States

    Contact: Study coordinator (Wes Booth) · wbooth@cahabaderm.com · 205-778-1564
    Contact: Principal Investigator (Vlada Groysman)
  • First OC Dermatology, Fountain Valley, California, United States

    Contact: Study coordinator (Jesus Ortega) · JOrtegaGallegos@dermcaremgt.com · 714-531-2966
    Contact: Principal Investigator (Vivian Laquer)
  • MedDerm Associates, San Diego, California, United States

    Contact: Study coordinator (Kristian Cadag) · kcadag@medderm.net · 619-243-7015
    Contact: Principal Investigator (Michelle Pelle)
  • Clinical Trials Research Institute, Thousand Oaks, California, United States

    Contact: Study coordinator (Shawn Ahoubim) · clinicaltrials@calderm.net · 888-367-1850
    Contact: Principal Investigator (Navid Ezra)
  • Encore Medical Research, Hollywood, Florida, United States

    Contact: Study coordinator (Yeniska Hall) · yhall@encoremedicalresearch.com · 954-400-1725
    Contact: Principal Investigator (Jerome Obed)
  • Mayo Clinic Jacksonville, Jacksonville, Florida, United States

    Contact: Study coordinator (Jarell C Hughes) · hughes.jarell@mayo.edu · 904-953-2000
    Contact: Principal Investigator (Ashley Wentworth)
  • Miami Derm and Laser Institute, Miami, Florida, United States

    Contact: Study coordinator (Swanee Cepero) · swaneec@miamidermlaser.com · 305-279-6060
    Contact: Principal Investigator (Jill Waibel)
  • Global Clinical Professionals, St. Petersburg, Florida, United States

    Contact: Study coordinator (Madelaine Perez) · mperez@researchgcp.com · 727-520-1427
    Contact: Principal Investigator (Wanda M Boote)
  • Dawes Fretzin Clinical Rea Group, Indianapolis, Indiana, United States

    Contact: Study coordinator (Michelle Riggs) · mgaidzik@ecommunity.com · +1 317 516 5030#102
    Contact: Principal Investigator (Kenneth Dawes)
  • Hamzavi Dermatology, Fort Gratiot, Michigan, United States

    Contact: Study coordinator (Lee Campbell) · lcampbell@hamzavi.com · 810-455-1600
    Contact: Principal Investigator (Iltefat Hamzavi)
  • Revival Research Institute, Troy, Michigan, United States

    Contact: Study coordinator (Madhuri Para) · mpara@rev-research.com · 248-564-1485
    Contact: Principal Investigator (Ali Moiin)
  • Skin Specialists PC, Omaha, Nebraska, United States

    Contact: Study coordinator (Schyler Schriever) · Schyler@LovelySkin.com · 402-334-7546
    Contact: Principal Investigator (Joel Schlessinger)
  • Las Vegas Dermatology, Las Vegas, Nevada, United States

    Contact: Study coordinator (Faith Limon) · ftrujillo@lvderm.com · +1 702 456 3120
    Contact: Principal Investigator (Harry Lawrence Greenberg)
  • Equity Medical, The Bronx, New York, United States

    Contact: Study coordinator (Luana Cabreja) · lcabreja@equity-med.com
    Contact: Principal Investigator (Michael Cameron)
  • Oregon Medical Research Center, Portland, Oregon, United States

    Contact: Study coordinator (Megan Lamey) · mlamey@oregonmedicalresearch.com · 503-245-0315
    Contact: Principal Investigator (Benjamin D Ehst)
  • International Clinical Research Tennessee LCC, Murfreesboro, Tennessee, United States

    Contact: Study coordinator (Miles Guy) · mguy@icresearch.net · 615-410-3450
    Contact: Principal Investigator (Christina Feser)
  • Bellaire Dermatology Associates, Bellaire, Texas, United States

    Contact: Study coordinator (Luis Leal Ruiz) · luis.leal@bellairedermatology.com · 832-553-2308
    Contact: Principal Investigator (Craig F Teller)
  • Center for Clinical Studies, Houston, Texas, United States

    Contact: Study coordinator (Perla Rivas) · privas@ccstexas.com · 713-528-8818
    Contact: Principal Investigator (Stephen K Tyring)
  • Austin Inst for Clinical Research, Pflugerville, Texas, United States

    Contact: Study coordinator (Tolga Han) · tolga.han@atxresearch.com · 512-259-2545
    Contact: Principal Investigator (Edward Lain)
  • ACRC Trials, Plano, Texas, United States

    Contact: Study coordinator (Jani Taylor) · JaniT@acrctrials.com · +1 972 354 1520
    Contact: Principal Investigator (Seemal Rohit Desai)
  • Virginia Clinical Research, Norfolk, Virginia, United States

    Contact: Study coordinator (Crystal Temple) · ctemple@vcrinc.org · 757-625-0151
    Contact: Principal Investigator (David M Pariser)
  • Novartis Investigative Site, Sydney, New South Wales, Australia

  • Novartis Investigative Site, Waitara, New South Wales, Australia

  • Novartis Investigative Site, Melbourne, Victoria, Australia

  • Novartis Investigative Site, Calgary, Alberta, Canada

  • Novartis Investigative Site, Winnipeg, Manitoba, Canada

  • Novartis Investigative Site, Mississauga, Ontario, Canada

  • Novartis Investigative Site, Newmarket, Ontario, Canada

  • Novartis Investigative Site, Toronto, Ontario, Canada

  • Novartis Investigative Site, Québec, Quebec, Canada

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Brest, France

  • Novartis Investigative Site, Rouen, France

  • Novartis Investigative Site, Toulouse, France

  • Novartis Investigative Site, Munich, Bavaria, Germany

  • Novartis Investigative Site, Bad Bentheim, Germany

  • Novartis Investigative Site, Hamburg, Germany

  • Novartis Investigative Site, Münster, Germany

  • Novartis Investigative Site, Ahmedabad, Gujarat, India

  • Novartis Investigative Site, Bangalore, Karnataka, India

  • Novartis Investigative Site, Belagavi, Karnataka, India

  • Novartis Investigative Site, Mysore, Karnataka, India

  • Novartis Investigative Site, Nashik, Maharashtra, India

  • Novartis Investigative Site, Ancona, AN, Italy

  • Novartis Investigative Site, Rozzano, MI, Italy

  • Novartis Investigative Site, Urayasu, Chiba, Japan

  • Novartis Investigative Site, Kofu, Yamanashi, Japan

  • Novartis Investigative Site, Niigata, Japan

  • Novartis Investigative Site, Amsterdam, North Holland, Netherlands

  • Novartis Investigative Site, Rotterdam, South Holland, Netherlands

  • Novartis Investigative Site, Barcelona, Spain